Misoprostol: New Frontiers; Benefits Beyond the Gastrointestinal Tract
- 1 January 1992
- journal article
- review article
- Published by Taylor & Francis in Scandinavian Journal of Rheumatology
- Vol. 21 (sup92) , 31-52
- https://doi.org/10.3109/03009749209101387
Abstract
Recent findings suggest that the protective role that misoprostol exerts in the gastrointestinal tract against nonsteroidal anti-innammatory drug (NSAID) damage may be extended to a variety of other tissues and other noxious stimuli including those mediated by molecules such as interleukin 1 (IL-1), tumor necrosis factor (TNF), and endotoxin. The protective effects of misoprostol outside the gastrointestinal tract may involve prevention of triggering activities that would otherwise initiate a sequence of tissue dvaging events. If this capacity of misoprostol to maintain homeostasis in a variety of settings is recognized, a cohesive pattern of action emerges. Numerous studies have shown that misoprostol is likely to act as a regulator within various cascades of immunological regulatory events. The in vitro and in vivo experimental data described in this paper suggest that the events which trigger episodes of pain and inflammation may be controllable by the administration of misoprostol. Mitigztion of adverse effects of certain NSAIDs on renal function and cartilage metabolism has also been observed. Demonstration of this latter phenomenon in the clinical setting will greatly benefit the patient if it is shown to modify the arthritis disease process. The therapeutic applications of misoprostol beyond the gastrointestinal tract appear to be among the most interesting of therapeutic advances offered by any class of compound in the next decade. Because of the inflammatory and pain processes associated with arthritis disease progression, particular emphasis and confirmation through further clinical study should be placed on the potential effect of misoprostol on chondroprotection and synergy with NSAIDs.Keywords
This publication has 40 references indexed in Scilit:
- Alteration of the cellular fatty acid profile and the production of eicosanoids in human monocytes by gamma‐linolenic acidArthritis & Rheumatism, 1990
- Prevention of Acute Graft Rejection by the Prostaglandin E1Analogue Misoprostol in Renal-Transplant Recipients Treated with Cyclosporine and PrednisoneNew England Journal of Medicine, 1990
- Circulating tumour necrosis factor‐α (cachectin) in myocardial infarctionJournal of Internal Medicine, 1989
- The mechanisms of action of nonsteroidal antiinflammatory drugsArthritis & Rheumatism, 1989
- EFFECTS OF THE PROSTAGLANDIN E1 ANALOG MISOPROSTOL ON CYCLOSPORINE NEPHROTOXICITYTransplantation, 1988
- Poster summariesDigestive Diseases and Sciences, 1986
- Misoprostol clinical pharmacologyDigestive Diseases and Sciences, 1985
- Synthesis of estradiol fatty acid esters by human breast tumors: Fatty acid composition and comparison to estrogen and progesterone receptor contentThe Journal of Steroid Biochemistry and Molecular Biology, 1985
- Cyclic AMP incudes synthesis of prostaglandin E1 in plateletsBiochimica et Biophysica Acta (BBA) - General Subjects, 1983
- Metabolism of arachidonic acid by platelets: utilization of arachidonic acid by human platelets in presence of linoleic and dihomo-γ-linolenic acidsZeitschrift Fur Ernahrungswissenschaft, 1978